SeaStar Medical Holding Corp - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
ICU Nasdaq 3841 https://seastarmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SeaStar Medical Holding Corp

SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update - May 15th, 2023 8:45 pm
SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023 - May 10th, 2023 12:00 pm
SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device - May 9th, 2023 8:05 pm
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury - Apr 19th, 2023 12:00 pm
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update - Mar 30th, 2023 11:23 pm
Presenting on the Emerging Growth Conference on March 22 Register Now - Mar 21st, 2023 11:00 am
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement - Mar 16th, 2023 12:00 pm
SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023 - Mar 15th, 2023 8:05 pm
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit - Feb 24th, 2023 1:05 pm
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury - Feb 15th, 2023 9:01 pm
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023 - Feb 14th, 2023 9:05 pm
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury - Feb 9th, 2023 1:19 pm
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Jan 31st, 2023 1:00 pm
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients - Jan 9th, 2023 1:25 pm
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) - Dec 29th, 2022 6:35 pm
SeaStar Medical, Nuwellis Ink US Licensing Pact For Acute Kidney Injury Device For Pediatric Patients - Dec 29th, 2022 2:02 pm
SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development - Dec 2nd, 2022 2:05 pm
SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors - Nov 29th, 2022 2:05 pm
SeaStar Medical Holding Corporation's (NASDAQ:ICU) top owners are individual investors with 51% stake, while49% is held by institutions - Nov 17th, 2022 1:27 pm
SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting - Nov 7th, 2022 5:30 pm